Class iii β-tubulin (TUBB3): More than a biomarker in solid tumors?

Current Molecular Medicine

Volumn 11, Issue 9, 2011, Pages 726-731

  Mariani, M ^a,b   Shahabi, S ^b   Sieber, S ^b   Scambia, G ^a   Ferlini, C ^a,b  

^a CATHOLIC UNIVERSITY   (Italy)

^b DANBURY HOSPITAL   (United States)

Author keywords

Biomarkers; Drug resistance; Poor outcome; Tubulin

Indexed keywords

BETA TUBULIN; BEVACIZUMAB; EPOTHILONE B; HEAT SHOCK PROTEIN 70; IXABEPILONE; NAVELBINE; PACLITAXEL; PROTEIN TUBB3; SEMAPHORIN; TUMOR MARKER; UNCLASSIFIED DRUG;

ANGIOGENESIS; CANCER CELL CULTURE; CANCER PATIENT; CANCER SURVIVAL; CYTOSKELETON; DNA FLANKING REGION; GENE OVEREXPRESSION; GENETIC REGULATION; HUMAN; HYPOGLYCEMIA; HYPOXIA; IN VITRO STUDY; INTERMEDIATE FILAMENT; LUNG CANCER; MICROFILAMENT; MICROTUBULE; NONHUMAN; OVARY CANCER; PROTEIN EXPRESSION; PROTEIN PROCESSING; REVIEW; TUMOR MICROENVIRONMENT;

ANIMALS; CELL HYPOXIA; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYPOGLYCEMIA; NEOPLASMS; TUBULIN; TUMOR MARKERS, BIOLOGICAL;

EID: 81055139797     PISSN: 15665240     EISSN: 18755666     Source Type: Journal    
DOI: 10.2174/156652411798062368     Document Type: Review

References (38)

1. Blay JY, Le Cesne A, Alberti L, Ray-Coquart I. Targeted cancer therapies. Bull. Cancer 2005; 92(2): E13-E18.
2. Kavallaris M, Kuo DY, Burkhart CA, et al. Taxol-resistant epithelial ovarian tumors are associated with altered expression of specific beta-tubulin isotypes. J Clin Invest 1997; 100(5): 1282-93.
3. Mozzetti S, Ferlini C, Concolino P, et al. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin. Cancer Res 2005; 11(1): 298-305.
4. Ferrandina G, Zannoni GF, Martinelli E, et al. Class III {beta}- Tubulin overexpression is a marker of poor clinical outcome in advanced ovarian cancer patients. Clin. Cancer Res 2006; 12(9): 2774-9.
5. Ohishi Y, Oda Y, Basaki Y, et al. Expression of beta-tubulin isotypes in human primary ovarian carcinoma. Gynecol. Oncol 2007; 105(3): 586-92.
6. Umezu T, Shibata K, Kajiyama H, et al. Taxol resistance among the different histological subtypes of ovarian cancer may be associated with the expression of class III betatubulin. Int J Gynecol Pathol 2008; 27(2): 207-12.
7. Seve P, Isaac S, Tredan O, et al. Expression of class III {beta}-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005; 11(15): 5481-6.
8. Seve P, Mackey J, Isaac S, et al. Class III beta-tubulin expression in tumor cells predicts response and outcome in patients with non-small cell lung cancer receiving paclitaxel. Mol Cancer Ther 2005; 4(12): 2001-7.
9. Seve P, Lai R, Ding K, et al. Class III beta-tubulin expression and benefit from adjuvant cisplatin/vinorelbine chemotherapy in operable non-small cell lung cancer: analysis of NCIC JBR.10. Clin. Cancer Res 2007; 13(3): 994-9.
10. Okuda K, Sasaki H, Dumontet C, et al. Expression of excision repair cross-complementation group 1 and class III beta-tubulin predict survival after chemotherapy for completely resected non-small cell lung cancer. Lung Cancer 2008; 62(1): 105-12.
11. Azuma K, Sasada T, Kawahara A, et al. Expression of ERCC1 and class III beta-tubulin in non-small cell lung cancer patients treated with carboplatin and paclitaxel. Lung Cancer 2009; 64(3): 326-33.
12. Hayashi Y, Kuriyama H, Umezu H, et al. Class III betatubulin expression in tumor cells is correlated with resistance to docetaxel in patients with completely resected non-smallcell lung cancer. Intern Med 2009; 48(4): 203-8.
13. Ikeda S, Takabe K, Suzuki K. Expression of ERCC1 and class IIIbeta tubulin for predicting effect of carboplatin/paclitaxel in patients with advanced inoperable non-small cell lung cancer. Pathol Int 2009; 59(12): 863-7.
14. Koh Y, Jang B, Han SW, et al. Expression of class III betatubulin correlates with unfavorable survival outcome in patients with resected non-small cell lung cancer. J Thorac Oncol 2010; 5(3): 320-5.
15. Dumontet C, Jordan MA, Lee FF. Ixabepilone: targeting betaIII-tubulin expression in taxane-resistant malignancies. Mol Cancer Ther 2009; 8(1): 17-25.
16. Rodriguez OC, Schaefer AW, Mandato CA, Forscher P, Bement WM, Waterman-Storer CM. Conserved microtubuleactin interactions in cell movement and morphogenesis. Nat Cell Biol 2003; 5(7): 599-609.
17. Ferlini C, Raspaglio G, Cicchillitti L, et al. Looking at drug resistance mechanisms for microtubule interacting drugs: does TUBB3 work? Curr Cancer Drug Targets 2007; 7(8): 704-12.
18. Yen TJ, Machlin PS, Cleveland DW. Autoregulated instability of beta-tubulin mRNAs by recognition of the nascent amino terminus of beta-tubulin. Nature 1988; 334(6183): 580-5.
19. Cleveland DW, Sullivan KF. Molecular biology and genetics of tubulin. Annu. Rev Biochem 1985; 54: 331-65.
20. Verdier-Pinard P, Pasquier E, Xiao H, et al. Tubulin proteomics: towards breaking the code. Anal Biochem 2009; 384(2): 197-206.
21. Tischfield MA; Engle EC. Distinct alpha- and beta-tubulin isotypes are required for the positioning; differentiation and survival of neurons: new support for the 'multi-tubulin' hypothesis. Biosci Rep 2010; 30(5): 319-30.
22. Kunishima S, Kobayashi R, Itoh TJ, Hamaguchi M, Saito H. Mutation of the beta1-tubulin gene associated with congenital macrothrombocytopenia affecting microtubule assembly. Blood 2009; 113(2): 458-61.
23. Bhattacharya R, Cabral F. Molecular basis for class V betatubulin effects on microtubule assembly and paclitaxel resistance. J Biol Chem 2009; 284(19): 13023-32.
24. Derry WB, Wilson L, Khan IA, Luduena RF, Jordan MA. Taxol differentially modulates the dynamics of microtubules assembled from unfractionated and purified beta-tubulin isotypes. Biochemistry 1997; 36(12): 3554-62.
25. Hari M, Yang H, Zeng C, Canizales M, Cabral F. Expression of class III beta-tubulin reduces microtubule assembly and confers resistance to paclitaxel. Cell Motil Cytoskeleton 2003; 56(1): 45-56.
26. Mozzetti S, Iantomasi R, De M, et al. Molecular mechanisms of patupilone resistance. Cancer Res 2008; 68(24): 10197-204.
27. Gan PP, Pasquier E, Kavallaris M. Class III beta-tubulin mediates sensitivity to chemotherapeutic drugs in non small cell lung cancer. Cancer Res 2007; 67(19): 9356-63.
28. McCarroll JA; Gan PP; Liu M; Kavallaris M. betaIII-tubulin is a multifunctional protein involved in drug sensitivity and tumorigenesis in non-small cell lung cancer. Cancer Res 2010; 70(12): 4995-5003.
29. Raspaglio G, Filippetti F, Prislei S, et al. Hypoxia induces class III beta-tubulin gene expression by HIF-1alpha binding to its 3' flanking region. Gene 2008; 409(1-2): 100-8.
30. Raspaglio G, De Maria I, Filippetti F, et al. HuR regulates beta-tubulin isotype expression in ovarian cancer. Cancer Res 2010; 70(14): 5891-900.
31. Hinman MN, Lou H. Diverse molecular functions of Hu proteins. Cell Mol Life Sci 2008; 65(20): 3168-81.
32. Meng Z, King PH, Nabors LB, et al. The ELAV RNA-stability factor HuR binds the 5'-untranslated region of the human IGF-IR transcript and differentially represses cap-dependent and IRES-mediated translation. Nucleic Acids Res 2005; 33(9): 2962-79.
33. Prislei S, Mozzetti S, Filippetti F, et al. From plasma membrane to cytoskeleton: a novel function for semaphorin 6A. Mol Cancer Ther 2008; 7(1): 233-241.
34. Cicchillitti L, Penci R, Di Michele M, et al. Proteomic characterization of cytoskeletal and mitochondrial class III beta-tubulin. Mol Cancer Ther 2008; 7(7): 2070-9.
35. Joe PA, Banerjee A, Luduena RF. The roles of cys124 and ser239 in the functional properties of human betaIII tubulin. Cell Motil Cytoskeleton 2008; 65(6): 476-86.
36. Suh JK; Robertus JD. Role of yeast flavin-containing monooxygenase in maintenance of thiol-disulfide redox potential. Methods Enzymol 2002; 348: 113-21.
37. Kerbel RS. Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. Breast 2009; 18: S41-S47.
38. Ferlini C, Raspaglio G, Mozzetti S, et al. The seco-taxane IDN5390 is able to target class III beta-tubulin and to overcome paclitaxel resistance. Cancer Res 2005; 65(6): 2397-405.